Physician profile
Amanda Downs
NPI 1699734327
$4,535.44
in general payments reported to CMS, 2019-2025
32 companies · $650 in 2025
The $650 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,092 · 2020: $817 · 2021: $450 · 2022: $254 · 2023: $610 · 2024: $663 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,923.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $919.78 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $688.91 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $520.46 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $393.47 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $379.64 | 2019-2025 | |
| Shield Therapeutics INC | $311.19 | 2022-2024 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.85 | 2019-2025 | Jardiance |
| Abbvie INC. | $98.73 | 2021-2025 | |
| Exact Sciences Corporation | $97.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Endo Pharmaceuticals INC. | $96.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $96.18 | 2020-2021 | |
| Amarin Pharma, INC. | $93.69 | 2019-2020 | |
| Glaxosmithkline, LLC. | $75.60 | 2022-2025 | Shingrix |
| Merck Sharp & Dohme LLC | $72.15 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Allergan, INC. | $59.67 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $54.73 | 2022 | |
| Corcept Therapeutics | $45.88 | 2024-2025 | Korlym |
| Dexcom, INC. | $44.11 | 2024-2025 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $43.92 | 2025 | Daybue |
| Idorsia Pharmaceuticals US INC | $42.10 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $39.11 | 2019 | |
| Astellas Pharma US INC | $35.68 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $34.17 | 2021 | |
| Genentech USA, INC. | $27.55 | 2019-2020 | |
| Boston Scientific Corporation | $17.01 | 2023 | Watchman Access System |
| Sunovion Pharmaceuticals INC. | $16.69 | 2021 | |
| Abbott Laboratories | $14.96 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $14.79 | 2024 | Voquezna |
| Currax Pharmaceuticals LLC | $14.59 | 2025 | Contrave |
| Sanofi Pasteur INC. | $14.09 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $11.82 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Downs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.